Acute Lymphocytic Leukemia

How can you enhance outcomes for your pediatric patients with acute lymphoblastic #leukemia? Drs. Maese & Rau (@RachelRau3) discuss optimal strategies for asparaginase dosing, toxicity mitigation & hypersensitivity/infusion reactions in this CME/MOC video https://t.co/LiIV35UumE (@PeerView)

📣Our latest @TheIACH webinar: Treatment of Acute Lymphoblastic Leukemia, with a Special Focus on the Role of Asparaginase and Conventional Chemotherapy Now available on-demand! 📽️View the full webinar for FREE ⬇️⬇️⬇️ https://t.co/HHXnQkR96h @Mohty_EBMT @NicBoissel (@TheIACH)

📣Join us NOW! https://t.co/lFA0FOOaQv Treatment of Acute Lymphoblastic Leukemia, with a Special Focus on the Role of Asparaginase and Conventional Chemotherapy Free registration @NicBoissel @Mohty_EBMT (@TheIACH)

📣Join us TODAY for @TheIACH webinar: Treatment of Acute Lymphoblastic Leukemia, with a Special Focus on the Role of Asparaginase and Conventional Chemotherapy Free registration➡️https://t.co/lFA0FOOaQv Tuesday, July 4 2023 5pm Paris 11am NY @NicBoissel @Mohty_EBMT (@TheIACH)

📣Join us TOMORROW for @TheIACH webinar: Treatment of Acute Lymphoblastic Leukemia, with a Special Focus on the Role of Asparaginase and Conventional Chemotherapy Free registration➡️ https://t.co/lFA0FOOaQv @NicBoissel @Mohty_EBMT (@TheIACH)

Induction failure in T-acute lymphoblastic #leukemia. Persistent residual disease at EOC, and TAL1 lesions coupled with Myc and Ras mutations define patients with dismal prognosis @JCO_ASCO @drdavidoconnor https://t.co/GegUMRQpZt (@LohiOlli)

📣Join us for the upcoming @TheIACH webinar: Treatment of Acute Lymphoblastic Leukemia, with a Special Focus on the Role of Asparaginase and Conventional Chemotherapy Free registration➡️ https://t.co/lFA0FOOaQv Tuesday, July 4 2023 5pm Paris 11am NY @NicBoissel @Mohty_EBMT (@TheIACH)

@drclaireroddie discusses obecabtagene autoleucel in patients w/ R/R B-cell acute lymphoblastic leukemia, details the key topline findings from the FELIX trial, and provides insights on unmet needs that remain for this patient population. #leusm https://t.co/Bpr4ChREua (@OncLive)

Join Drs @AmeliaLangston and Bijal Shah as they discuss CAR T-cell therapy for B-cell acute lymphoblastic leukemia, including clinical trials and real-world experience from their centers. https://t.co/bch33fwIsc (@Medscape)

WATCH: @RoloffGreg, of @UChicagoMed, discusses real-world outcomes from treatment with brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. https://t.co/TdZaSk61zY (@OncLive)

Join Drs @AmeliaLangston and Bijal Shah as they discuss CAR T-cell therapy for B-cell acute lymphoblastic leukemia, including clinical trials and real-world experience from their centers. #OncTwitter https://t.co/N5F5CB2KvY (@MedscapeOnc)

According to data presented at #ASCO2023 by @drclaireroddie, 76% of adults with relapsed or refractory B-cell acute lymphoblastic leukemia achieved complete response to treatment with obecabtagene autoleucel. https://t.co/N8K8LneHjT (@HemOncToday)

Watch Drs. Maese & Rau (@RachelRau3) discuss available asparaginase formulations and how to effectively utilize them in the management of pediatric acute lymphoblastic #Leukemia https://t.co/LiIV35UumE #MedEd #MedTwitter (@PeerView)

#PediatricALL #Acutelymphoblasticleukemia 🎉miR-16-5p enhances sensitivity to RG7388 through targeting PPM1D expression (WIP1) in Childhood Acute Lymphoblastic Leukemia 👉https://t.co/zbSpStVoKn @AdeleKFielding @LLSusa @garciamanero @TapKadia @sanamloghavi @iannisaifantis1 (@cdrjournal)

Brexu-cel elicited high rates of complete remission s/ MRD negativity in real-world patients w/ R/R B-cell acute lymphoblastic leukemia who received the CAR T-cell product as post-approval, standard-of-care treatment. @RoloffGreg @UChicagoMed #ASCO23 https://t.co/q7FBOJSe33 (@OncLive)

Obecatagene autoleucel was associated with a 76% complete response (CR)/CR with incomplete count recovery rate in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. @drclaireroddie @uclcancer #ASCO2023 #ASCO23 #leusm https://t.co/1ZUt8ewXdp (@OncLive)

Brexu-cel elicited high rates of complete remission s/ MRD negativity in real-world patients w/ R/R B-cell acute lymphoblastic leukemia who received the CAR T-cell product as post-approval, standard-of-care treatment. @RoloffGreg @UChicagoMed @ASCO #ASCO23 https://t.co/DbYMoQThvh (@OncLive)

What does the future look like for the treatment of Ph+ acute lymphoblastic #leukemia? Find out during sessions led by @DrHKantarjian, @NicholasShortMD and Dr Elias Jabbour at @Medthority’s CME-accredited symposium TODAY! Food served from 6:30 pm. #ALLsm #hematology #ASCO23 (@MeganELee11)

Findings presented at #ASCO23 suggest disparities in access to centers with specialization in acute lymphoblastic leukemia. Healio spoke with @LoriMuffly of @StanfordMed to learn more. https://t.co/6JQSsxKO9j (@HemOncToday)

75% event free survival at 1 year for elderly ( age >70 yr) with acute lymphoblastic leukemia treated without chemotherapy is simply an amazing result Blina + Ino is a powerful combination of immunotherapy for Pre B - ALL #ASCO23 👇 (@Satyayadav__)

https://t.co/qegWWe7qaF: Mini-hyper-CVD with venetoclax (Ven) for patients with relapsed/refractory (R/R) Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL): A phase II study @MDAndersonNews #ASCO23 @DrHKantarjian (@TalhaBadarMD)

Our experts will present their latest research at #ASCO23, including studies of acute lymphoblastic leukemia, KRAS G12C-mutated tumors and racial disparities in GI cancers. Learn about them here: https://t.co/PUUSItVLBL @DrShubhamPant @ColonCancerDoc @ASCO #EndCancer (@MDAndersonNews)

#ESHALL2023: another outstanding day with lots of interaction, questions & high scientific exchange! 3rd Translational Research Conference: ACUTE LYMPHOBLASTIC LEUKAEMIA Chairs: @CoolsJn, @DombretHerve, @AdeleKFielding, @MRLitzow ➡https://t.co/0alWOKoVPh #ESHCONFERENCES #LEUsm (@ESHaematology)

The ESH team is ready to welcome you for #ESHALL2023! See you tomorrow at 8:30 in Berlin 🇩🇪 3rd Translational Research Conference: ACUTE LYMPHOBLASTIC LEUKAEMIA Chairs: @CoolsJn, @DombretHerve, @AdeleKFielding, @MRLitzow More info ➡ https://t.co/0alWOKoVPh #ESHCONFERENCES #LEUsm (@ESHaematology)

Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia? https://t.co/4BVQOY7Y4x #ALL #leusm (@smbenlazar)

Targeted Therapy in Acute Lymphoblastic Leukaemia https://t.co/o0fwVnwO0t #mdpijpm via @JPM_MDPI #ALL #leusm (@smbenlazar)

Title: DONOR-DERIVED CD5 CAR T CELLS FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA... by Jing Pan EHA Library; Jun 08 2023; 387816 https://t.co/f1SiX3CiYN #EHA23 (@smbenlazar)

📣 #ESHALL2023 STARTS THIS WEEK! REGISTER NOW & join @CoolsJn, @DombretHerve, @AdeleKFielding, @MRLitzow & the faculty in Berlin 🇩🇪 ➡ https://t.co/0alWOKoVPh 🗓️ Friday May 19th 3rd Translational Research Conference: ACUTE LYMPHOBLASTIC LEUKAEMIA #ESHCONFERENCES #LEUsm @dgho_eV (@ESHaematology)

CD19 chimeric antigen receptor T-cell therapy in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia without complete molecular response at 3 months https://t.co/VwIXGkmkTl #leusm (@smbenlazar)

Tumor lysis syndrome #TLS A true medical emergency in children with ⏺️Acute lymphoblastic leukemia with hyperleukocytosis ⏺️Acute leukemia with high tumor burden ⏺️Burkitt lymphoma ⏺️T cell leukemia/lymphoma ⏺️other NHL Timely snd correct management can save lives 👇 (@Satyayadav__)

From a combination therapy for acute lymphoblastic leukemia to new insights into anaplastic thyroid cancer to a promising new treatment approach for pancreatic cancer, learn about the latest advances: https://t.co/Mjs8IJaXh6 @DrHKantarjian @JenniferWangMD @Dr_Di_Zhao #EndCancer (@MDAndersonNews)

⚠ #ESHALL2023 STARTS NEXT WEEK! REGISTRATION STILL OPEN: DON'T MISS THE OPPORTUNITY➡ https://t.co/0alWOKoVPh May 19-21, Berlin 🇩🇪 3rd Translational Research Conference: ACUTE LYMPHOBLASTIC LEUKAEMIA Chairs: @CoolsJn @DombretHerve @AdeleKFielding @MRLitzow #ESHCONFERENCES #LEUsm (@ESHaematology)

🥳New review "miR-16-5p enhances sensitivity to RG7388 through targeting PPM1D expression (WIP1) in Childhood Acute Lymphoblastic Leukemia" Open Access: https://t.co/RjK23ZpUhQ @pebarba @smbenlazar @FadiHaddad_MD @NicholasShortMD @NitinJainMD @garciamanero @sanamloghavi (@cdrjournal)

Nelarabine and optimisation of therapy for T-cell acute lymphoblastic #leusm #lymsm https://t.co/SWPAwWYyqJ (@HayderSaeed_MD)

🩸 Researchers with Dr. @TalhaBadarMD highlight the evolving treatment landscape of Philadelphia chromosome-positive acute lymphoblastic #leukemia and what to look for in the future. 📖 #review @MayoClinic | https://t.co/MiitN9Tn7O (@Hema_News)

CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study https://t.co/jCCH7OfjhM #ALL #leusm (@smbenlazar)

Cuplike nuclei in B-cell acute lymphoblastic leukemia with DUX4 rearrangement https://t.co/FeW8AfnyhC (@smbenlazar)

Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against <i>FLT3</i>- mutant acute myeloid leukemia and <i>KMT2A</i>-rearranged acute lymphoblastic leukemia | Haematologica https://t.co/XNIJekIFGt (@SCTNB)

Measurable residual disease in acute lymphoblastic leukemia: How low is low enough? https://t.co/gBCD361pPh Important read for anyone practicing ALL. @hemedoc so well-written. #leuksm (@uroosaibrahim)

Cuplike nuclei in B-cell acute lymphoblastic leukemia with DUX4 rearrangement https://t.co/FeW8AfnyhC (@smbenlazar)

788 Prediction of Initial Risk Group, B/T Subtype, and ETV6-RUNX1 Translocation in Pediatric Acute Lymphoblastic Leukemia By Deep Convolutional Neural Network Analysis of Giemsa-Stained Whole Slide Images https://t.co/hgPKIikDXG (@nishihori)

Changes in the IKZF1 gene are linked to poor outcomes for children with B-cell acute lymphoblastic leukemia. Dr. Ruth Wang'ondu will explain why Dec. 10 at 10:15 am CT https://t.co/xjgc1o0IyP @wang_rwang #ASH22 (@StJudeResearch)